{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": {
    "pdf_name": "Liu_et_al.__2024_"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "RIV4 contains 45 \u00b5g HA/dose/strain, compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "relevance_explanation": "This quote directly states that RIV4 (Flublok) contains 45 \u00b5g of HA per strain, which is three times the amount in standard-dose IIV4 and ccIIV4 (15 \u00b5g), supporting the claim about antigen content.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "relevance_explanation": "This quote provides evidence that RIV4 (Flublok) led to greater immunogenicity (higher antibody responses) compared to standard-dose flu vaccines, supporting the second part of the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}